Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Repligen Community
NasdaqGS:RGEN Community
1
Narratives
written by author
0
Comments
on narratives written by author
12
Fair Values set
on narratives written by author
Community Investing Ideas
Repligen
Popular
Undervalued
Overvalued
Repligen
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
Expanding Dual Manufacturing And APAC Presence Will Drive Future Success
Key Takeaways Increased focus on innovative, higher-margin products and expanded global manufacturing aims to strengthen recurring revenue and drive resilient, long-term growth. Strategic diversification across modalities and regions reduces reliance on any one market, supporting margin expansion and consistent operational performance.
View narrative
US$179.72
FV
29.5% undervalued
intrinsic discount
15.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
about 15 hours ago
author updated this narrative
Your Valuation for
RGEN
RGEN
Repligen
Your Fair Value
US$
Current Price
US$126.64
66.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-14m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.3b
Earnings US$168.9m
Advanced
Set Fair Value